|
|
Vaccine Detail
|
VBI-2902a |
| Vaccine Information |
- Vaccine Name: VBI-2902a
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: VBI Vaccines Inc.
- Vaccine Ontology ID: VO_0005238
- Type: Virus Like Particle
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: SARS-CoV-2 spike glycoprotein (S protein) (NCT04773665)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Baboon Response
- Immune Response: Antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19. (Fluckiger et al., 2021)
|
| References |
Fluckiger et al., 2021: Anne-Catherine Fluckiger 1, Barthelemy Ontsouka 2, Jasminka Bozic 2, Abebaw Diress 2, Tanvir Ahmed 2, Tamara Berthoud 2, Anh Tran 3, Diane Duque 3, Mingmin Liao 4, Michael McCluskie 3, Francisco Diaz-Mitoma 5, David E Anderson 5, Catalina Soare 2. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. . 2021; ; . [PubMed: 34304928].
NCT04773665: Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a) [https://clinicaltrials.gov/ct2/show/NCT04773665]
|
|
